Table 1.
Baseline characteristics of the study population
| Parameters | No. of patients | % |
|---|---|---|
| Sex | ||
| Male | 23 | 67.6 |
| Female | 11 | 32.4 |
| PS score | ||
| 0-1 | 22 | 64.7 |
| 2 | 12 | 35.3 |
| Pathological diagnosis | ||
| Adenocarcinoma | 24 | 70.6 |
| Squamous cell carcinoma | 6 | 17.6 |
| Unknown | 4 | 11.8 |
| Smoking status | ||
| Smoker | 14 | 41.2 |
| Non-smoker | 20 | 58.8 |
| EGFR-TKI agent | ||
| Gefitinib | 19 | 55.9 |
| Erlotinib | 15 | 44.1 |
| EGFR-TKI preference | ||
| Second-line | 18 | 52 |
| Above second-line | 16 | 48 |
| EGFR-TKI duration | ||
| ≥6 Months | 12 | 35.3 |
| <6 Months | 22 | 64.7 |
Note: EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.